Obstetric antiphospholipid antibody syndrome

1,603 views
1,392 views

Published on

Obstetric antiphospholipid
antibody syndrome

Published in: Health & Medicine
0 Comments
18 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,603
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
190
Comments
0
Likes
18
Embeds 0
No embeds

No notes for slide

Obstetric antiphospholipid antibody syndrome

  1. 1. Benha University Hospital Email: elnashar53@hotmail.com Aboubakr Elnashar
  2. 2.  An acquired autoimmune disorder characterized by -moderate to high levels of antiphospholipid antibodies (LA or aCl or a-ß2GPI) & -specific clinical features (arterial or venous thrombosis or pregnancy morbidity) (Miyakis et al, 2006)  20 antibodies  First description: 1983 (Graham Hughes) Aboubakr Elnashar
  3. 3. Primary: 50% other features of connective tissue disease are absent Secondary: 50% to connective tissue disease e.g. SLE Aboubakr Elnashar
  4. 4. Epidemiology  General population: 2-4%. increases with age and chronic disease  Recurrent fetal loss: 15 %  SLE: 30%  aCL antibodies: more common than LA (aCL 5X more than LA) Aboubakr Elnashar
  5. 5. 1. Recurrent pregnancy loss. 25%. Majority: in 1st T after the establishment of FHR activity. 15% of RPL 2. Preeclampsia: 15-50%. 15% of severe PET before 34 w have APL Ab 3. IUGR: 30% 4. Preterm labor 5. Maternal thrombosis (including strokes) Aboubakr Elnashar
  6. 6. Mechanisms 1. Inhibition of trophoblastic function& differentiation (Bose et al, 2005) 2. Activation of complement pathways at the maternal–fetal interface: local inflammatory response (Salmon et al, 2003) 3. In later pregnancy, thrombosis of the uteroplacental vasculature (Peaceman et al, 1993). neither universal nor specific (Jivraj & Rai, 2003) Aboubakr Elnashar
  7. 7. Controversy.  aPl is responsible for implantation failure. aPL is 23% in females referred for IVF Vs 2% in fertile females (Chilcott et al,2000)  Routine screening for aPL among women undergoing IVF-ET is not warranted (Branch et al,2003) Aboubakr Elnashar
  8. 8. Postpartum syndrome Rare Manifestations Pleuropulmonary disease Fever Cardiac manifestations Mechanism Unknown extensive Img and C3 deposition in myocardium Aboubakr Elnashar
  9. 9. Aboubakr Elnashar
  10. 10. Sydney clinical criteria for APS (2006)  At least 1 clinical and 1 laboratory criterion.  Not if there is <12 W or > 5 years between +ve aPLab and the clinical manifestation Aboubakr Elnashar
  11. 11. I. Clinical 1. Vascular thrombosis One or more clinical episodes of arterial, venous, or small-vessel thrombosis in any tissue or organ confirmed by imaging, Doppler studies, or histopathology, with the exception of superficial venous thrombosis. For histopathologic confirmation, thrombosis should be present without significant evidence of inflammation of the vessel wall. Aboubakr Elnashar
  12. 12. 2. Pregnancy morbidity (a) One or more unexplained deaths of a morphologically normal fetus at or beyond the 10th w, with normal fetal morphology documented by US or by direct examination of the fetus, or (b) One or more premature births of a morphologically normal neonate at or before the 34th w because of severe preeclampsia or eclampsia or severe placental insufficiency, or (c) Three or more unexplained consecutive spontaneous abortions before the 10th w, with maternal anatomic or hormonal abnormalities and paternal and maternal chromosomal causes excluded. N.B: in practice evaluation after 2 early miscarriage Aboubakr Elnashar
  13. 13. 2. Comparison of laboratory criteria of APS. Test Sapporo criteria (1999) Sydney criteria (2006) LACs Screening, mixing, and confirmation tests Two or more occasions at least 6 w Apart Screening, mixing, and confirmation tests Two or more occasions at least 12 w Apart aCL Ab Detected by standardized ELISA IgG and/or IgM Medium or high titer Two or more occasions at least 6 w apart Detected by standardized ELISA IgG and/or IgM Medium or high titer (>40 units titer or >99th percentile) Two or more occasions at least 12 w apart Anti- ß2GPI Ab IgG and/or IgM Titer >99th percentile Two or more occasions at least 12 weeks apart Aboubakr Elnashar
  14. 14. Interpretation: •A repeat tests at least 6 (12) W apart. {Individuals may have transiently positive test because a low to mid positive level can be due to viral illness and revert to normal& those with an initial negative test may be in the transient negative phase of their aPL cycle.} •LA, aCL and aβ2GPI testing are all required for the accurate diagnosis •Once APS is diagnosed, serial aPL testing is not useful Aboubakr Elnashar
  15. 15. •LA: positive or negative more specific. aCL: international units. more sensitive Titer is related to risk of fetal loss (Rai et al,1995) •IgG Ab more specific than IgM. better predictors of fetal outcome (Lockwood et al,1986) -IgA -no greater risk (Silver et al 1996). Aboubakr Elnashar
  16. 16. laboratory data-based classification system International Consensus Guidelines, 2006 Category Criteria I More than 1 laboratory criterion present in any combination IIa LA present, only IIb aCL present, only IIc anti-β2GPI present, only Aboubakr Elnashar
  17. 17. Controversial points in interpreting -Low positive IgG AcL Ab: No greater risk for APA related events (Silver et al, 1996). should be regarded as of questionable clinical significance (Branch et al,2003) should be included in the diagnosis of obstetric APS. (Gardiner et al, 2013) Aboubakr Elnashar
  18. 18. Obstetric indications: 1. Unexplained stillbirth 2. Recurrent pregnancy loss 3.Unexplained 2nd or 3rd T fetal death 4. IUGR 5. Severe preeclampsia at less than 34 w. 6. Placental abruption (previous or current) Aboubakr Elnashar
  19. 19. .Non-obstetric indication 1.False positive serologic test for syphilis 2.Autoimmune diseases: SLE, thrombocytopenia 3.Unexplained thrombosis 4.Haemolytic anaemia 5.Stroke, especially between 25-50 yr 6.Livedo reticularis Livedo reticularis Aboubakr Elnashar
  20. 20. Aboubakr Elnashar
  21. 21. A. Before pregnancy: Pre-conceptional counseling 1. Clinical: review med and obs history, asses other risk factors, obesity, age 2. Lab: Confirm persistent aPLab Assess R function CBC: anaemia thrompocytopenia 3. Treatment Postpone pregnancy if thrombotic event <6 month Initial low dose aspirin [increase success]Aboubakr Elnashar
  22. 22. B. During pregnancy  Objectives: Improve maternal & fetal-neonatal outcome by preventing complications Reduce or eliminate the maternal thrombotic risk 1. TVS: confirm live embryo at 5.5-6.5 W 2. Continue low dose aspirin 3. Initial heparin treatment Aboubakr Elnashar
  23. 23. Clinical care ANV/4 W until 20W then /1-2 W Monitor for fetal death, PET, IUGR Diagnostic tests U/S:/4W beginning at 20 W. Assess fetal growth & AFV Fetal surveillance: weekly from 30W. CTG, Uterine a Doppler: at 20 for prediction of PET If early diastolic notch seen: do 2 weekly growth scans due to high risk of IUGR Platelet count Aboubakr Elnashar
  24. 24. Medications: Low dose aspirin (75 mg) in combination with heparin is the first line treatment (MRCOG, 2011) Start with the positive pregnancy test till 34 w. -Success: 70% (Rai et al,1997) -Reduces the miscarriage rate by 54% (Empson et al, Cochrane Database Syst Rev, 2005) Aboubakr Elnashar
  25. 25. Heparin: Complications: Hemorrhage Thrombocytopenia: Rare Osteopenia: Loss in BMD of the lumbar spine is similar to physiological osteopenia in untreated pregnancies Aboubakr Elnashar
  26. 26. Un-fractionated heparin Vs LMWH: •LMWH is widely used in Europe, whereas cost considerations limit its use in other countries. •No significant difference in BMD or live birth rate (Farquharson,2000) LMWH advantages once daily less thrombocytopenia osteopenia Aboubakr Elnashar
  27. 27. Dose: A. No history of thrombosis: Standard heparin: 1st T: 5000-10000 U /12 h 2nd and 3rd T: 10000 U/12 hrs LMWH: Enoxaparin (clexan) 20 mg once daily Dalteprin 5000 U once daily. Aboubakr Elnashar
  28. 28. B. History of thrombosis Standard heparin: /8-12 hrs {maintain the midinterval heparin levels in the therapeutic range}. (Heparin level = anti-factorXa levels.) Women without a LA in whom APTT is normal can be observed using APTT. LMWH Enoxaparine: 0.5 mg/kg /12 h or 40 mg once daily. Aboubakr Elnashar
  29. 29. IV immunoglobulin: Expensive No benefit relative to heparin & low dose aspirin. Reserved for cases refractory to aspirin & heparin (Jivaraj & Rai,2003) Corticosteroids (prednisone): abandoned {do not improve the live birth significant maternal & fetal morbidity} (Laskin et al,1997). Warfarin: History of recurrent thrombosis or cerebral thrombosis (Branch et al, 2003) Aboubakr Elnashar
  30. 30. C. Postpartum  History of thrombosis: Warfarin thromboprophylaxis as soon as the patient is clinically stable after delivery (International normalized ratio (INR) of 3 is desirable). No history of thrombosis: UK: Heparin for 5 d USA: anticoagulant for 6 w. Breast feeding: Heparin & warfarin: safe Contraception estrogen-containing are contraindicated. Aboubakr Elnashar
  31. 31. Women refractory to aspirin & heparin (Branch et al,2003). Full anticoagulation in the next pregnancy if failed: IV immunoglobulin: {antiidiotypic down-regulation of auto-antibody production} Aboubakr Elnashar
  32. 32. • For diagnosis: 2 1 of 2 clinical criteria (thrombosis or pregnancy morbidity) & 1 of 3 laboratory criteria (medium to high titer of aCL or positive LA or Anti-ß2GPI Ab) • For treatment: 2 low dose aspirin & heparin starting with positive pregnancy test till 34 w. Aboubakr Elnashar
  33. 33. Aboubakr Elnashar

×